Conference Coverage

VIDEO: Does genitourinary syndrome of menopause capture all the symptoms?


 

AT NAMS 2017

– Genitourinary syndrome of menopause (GSM) replaced vulvovaginal atrophy in 2014 as a way to describe the changes to the genital and urinary tracts after menopause, but preliminary research shows it may be missing some symptoms.

In 2015, Amanda Clark, MD, a urogynecologist at the Kaiser Center for Health Research in Portland, Ore., and her colleagues surveyed women aged 55 years and older about their vulvar, vaginal, urinary, and sexual symptoms within 2 weeks of a well-woman visit to their primary care physician or gynecologist in the Kaiser system. In total, 1,533 provided valid data.

The researchers then used factor analysis to see if the symptoms matched up with GSM. If GSM is a true syndrome and only a single syndrome, then all of the factors would fit together in a one-factor model, Dr. Clark explained at the annual meeting of the North American Menopause Society. Instead, the researchers found that a three-factor model – with vulvovaginal symptoms of irritation and pain in one group, urinary symptoms in another group, and vaginal discharge and odor in a third group – fit best with the symptoms reported in their survey.

“This work is very preliminary and needs to be replicated in many other samples and looked at carefully,” Dr. Clark said in an interview. “But what we think is that genitourinary syndrome of menopause is a starting point.”

The study was funded by a Pfizer Independent Grant for Learning & Change and the North American Menopause Society. Dr. Clark reported having no relevant financial disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

On Twitter @maryellenny

Recommended Reading

Anabolic agents for osteoporosis have limited role so far
MDedge ObGyn
2017 Update on female sexual dysfunction
MDedge ObGyn
Focus on lifestyle to manage menopause symptoms after breast cancer
MDedge ObGyn
Study finds low risk for jaw osteonecrosis with denosumab for postmenopausal osteoporosis
MDedge ObGyn
Sleep issues vary by menopausal status
MDedge ObGyn
WHI hormone trials offer reassurance on long-term mortality risk
MDedge ObGyn
Gap in osteoporosis diagnosis and treatment stirs concern
MDedge ObGyn
Time to take the fear out of the hormone therapy conversation
MDedge ObGyn
Oral bioidentical combo improves quality of life, vasomotor symptoms
MDedge ObGyn
CBT for insomnia and hot flashes lifts mood in midlife
MDedge ObGyn